Mimedx Group, INC 10-Q quarterly reports

MiMedx Group, Inc. announced its second quarter 2026 financial results, highlighting continued growth in its Surgical segment despite an overall revenue decline driven by its Wound care division.

MiMedx Group, Inc. reported robust third-quarter 2025 results with net sales increasing 35.3% and net income more than doubling year-over-year, driven by strong performance in both Wound and Surgical product portfolios.

MiMedx Group announced a 13.1% increase in net sales for Q2 2025, reaching $98.6 million, but reported a 45.4% decrease in net income due to the absence of prior year's non-recurring benefits and increased operating expenses, while facing potential significant impacts from proposed CMS reimbursement changes.

MiMedx Group, Inc. announced a 4% increase in net sales for the first quarter of 2025, driven by growth in its surgical product line, while maintaining a strong cash position.

MiMedx Group, Inc. announced a 2.9% year-over-year increase in net sales for the third quarter of 2024, reaching $84.1 million, with growth primarily in private office settings and balanced between wound and surgical products.

MiMedx Group, Inc. announced a 7.3% year-over-year increase in net sales for the second quarter of 2024, driven by growth in both wound and surgical product lines.

MiMedx Group's first quarter of 2024 saw a significant 18.2% increase in net sales year-over-year, alongside improved profitability and a strategic debt refinancing.